# US 2013/0296422 A1 · Novel Dihydroxybenzene Derivatives and Antiprotozoal Agent Comprising Same as Active Ingredient

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0296422 A1
- Document ID: US20130296422A1
- Status: Published application
- Kind: A1
- Application number: 13/882,647
- Filed: 2011-11-01
- Published: 2013-11-07
- Earliest claimed: 2010-11-01
- Assignees: aRigen Pharmaceuticals, Inc.
- Inventors: Hiroyuki Saimoto; Kiyoshi Kita; Yoshisada Yabu; Masaichi Yamamoto
- Web page: https://patentgrep.com/patent/US20130296422A1

## CPC

- C07C 255/53: containing cyano groups and hydroxy groups bound to the carbon skeleton
- A61K 31/047: having two or more hydroxy groups, e.g. sorbitol
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 33/00: Antiparasitic agents
- C07C 47/27: containing six-membered aromatic rings
- C07C 47/56: containing hydroxy groups
- C07C 47/575: containing ether groups, [IMAGE cpc-sch-C07C-0958.gif] groups,[IMAGE cpc-sch-C07C-0959.gif] groups, or[IMAGE cpc-sch-C07C-0960.gif] groups
- C07C 49/248: having unsaturation outside the aromatic rings
- C07C 49/258: containing —CHO groups
- C07C 49/835: having unsaturation outside an aromatic ring
- C07C 49/84: containing ether groups, [IMAGE cpc-sch-C07C-0958.gif] groups,[IMAGE cpc-sch-C07C-0959.gif] groups, or[IMAGE cpc-sch-C07C-0960.gif] groups
- C07C 59/74: containing —CHO groups
- C07C 59/90: containing singly bound oxygen-containing groups
- C07C 69/738: Esters of keto-carboxylic acids {or aldehydo-carboxylic acids}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Novel compounds below are useful for preventing or treating diseases caused by protozoans. At least one of a compound represented by Formula (I) (wherein, X represents a hydrogen atom or a halogen atom; R1 represents a hydrogen atom; R2 represents a hydrogen atom or a C1-7 alkyl group; R3 represents —CHO, —C(═O)R5, —COOR5 (wherein R5 represents a C1-7 alkyl group), —CH2OH or —COOH; and R4 represents a C1-16 alkyl group having one or more substituents on a terminal carbon atom and/or non-terminal carbon atom(s), a C2-16 alkenyl group having one or more substituents on a terminal carbon atom and/or non-terminal carbon atom(s), or a C2-16 alkynyl group having one or more substituents on a terminal carbon atom and/or non-terminal carbon atom(s)), an optical isomer thereof, and a pharmaceutically acceptable salt is used.

## Claims

### Claim 1

A compound represented by Formula (I), an optical isomer thereof, and a pharmaceutically acceptable salt thereof:
wherein,
X represents a hydrogen atom or a halogen atom;
R1 represents a hydrogen atom;
R2 represents a hydrogen atom or a C1-7 alkyl group;
R3 represents —CHO, —C(═O)R5, —COOR5 (wherein R5 represents a C1-7 alkyl group), —CH2OH or —COOH; and
R4 represents a C1-16 alkyl group having one or more substituents on a terminal carbon atom and/or non-terminal carbon atom(s), a C2-16 alkenyl group having one or more substituents on a terminal carbon atom and/or non-terminal carbon atom(s), or a C2-16 alkynyl group having one or more substituents on a terminal carbon atom and/or non-terminal carbon atom(s).

### Claim 2 (depends on 1)

The compound, optical isomer thereof, and pharmaceutically acceptable salt thereof of claim 1, wherein the one or more substituents of R4 are each any one of —COOH, —COORa (wherein Ra represents a C1-7 alkyl group), —CHO, —COOCH2CH(OH)CH2OH, —COO—CH2—Rb (wherein Rb represents a group formed by removing one hydrogen atom on a carbon atom of aromatic hydrocarbons, such as benzene, naphthalene, and anthracene), —O—CO-Rc (wherein Rc represents a C1-7 alkyl group), —OH, —O-Rd (Rd represents a C1-7 alkyl group), —O—CH2—O—CH3, —HET (HET represents a group formed by removing one hydrogen atom on a carbon or nitrogen atom of heterocyclic compounds), and —O-HET (HET is defined as above).

### Claim 3

A pharmaceutical composition comprising: as an active ingredient, at least one of a compound represented by Formula (I), an optical isomer thereof, and a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier:
where,
X represents a hydrogen atom or a halogen atom;
R1 represents a hydrogen atom;
R2 represents a hydrogen atom or a C1-7 alkyl group;
R3 represents —CHO, —C(═O)R5, —COORS (wherein R5 represents a C1-7 alkyl group), —CH2OH or —COOH; and
R4 represents a C1-16 alkyl group having one or more substituents on a terminal carbon atom and/or non-terminal carbon atom(s), a C2-16 alkenyl group having one or more substituents on a terminal carbon atom and/or non-terminal carbon atom(s), or a C2-16 alkynyl group having one or more substituents on a terminal carbon atom and/or non-terminal carbon atom(s).

### Claim 4 (depends on 3)

The pharmaceutical composition of claim 3, wherein the one or more substituents of R4 is any one of —COOH, —COORa (wherein Ra represents a C1-7 alkyl group), —CHO, —COOCH2CH(OH)CH2OH, —COO—CH2—Rb (wherein Rb represents a group formed by removing one hydrogen atom on a carbon atom of aromatic hydrocarbons, such as benzene, naphthalene, and anthracene), —O—CO-Rc (wherein Rc represents a C1-7 alkyl group), —OH, —O-Rd (wherein Rd represents a C1-7 alkyl group), —O—CH2—O—CH3, —HET (wherein HET represents a group formed by removing one hydrogen atom on a carbon or nitrogen atom of heterocyclic compounds), and —O-HET (wherein HET is defined as above).

### Claim 5 (depends on 3, 4)

The pharmaceutical composition of claim 3 or 4, further comprising glycerol.

### Claim 6

An agent for preventing or treating a disease caused by a protozoan comprising: as an active ingredient, at least one of a compound represented by Formula (I), an optical isomer thereof, and a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier:
wherein,
X represents a hydrogen atom or a halogen atom;
R1 represents a hydrogen atom,
R2 represents a hydrogen atom or a C1-7 alkyl group,
R3 represents —CHO, —C(═O)R5, —COORS (wherein R5 represents a C1-7 alkyl group), —CH2OH or —COOH, and
R4 represents a C1-16 alkyl group having one or more substituents on a terminal carbon atom and/or non-terminal carbon atom(s), a C2-16 alkenyl group having one or more substituents on a terminal carbon atom and/or non-terminal carbon atom(s), or a C2-16 alkynyl group having one or more substituents on a terminal carbon atom and/or non-terminal carbon atom(s).

### Claim 7 (depends on 6)

The agent of claim 6, wherein the protozoans is Trypanosoma.

### Claim 8 (depends on 6)

The agent of claim 6, wherein the protozoans is Cryptosporidium.

### Claim 9 (depends on 6, 7, 8)

The agent of any one of claims 6 to 8, further comprising glycerol.

### Claim 10

A kit comprising: as an active ingredient,
at least one of a compound represented by Formula (I), an optical isomer thereof, and a pharmaceutically acceptable salt thereof, and instructions for use:
wherein,
X represents a hydrogen atom or a halogen atom;
R1 represents a hydrogen atom;
R2 represents a hydrogen atom or a C1-7 alkyl group;
R3 represents —CHO, —C(═O)R5, —COORS (wherein R5 represents a C1-7 alkyl group), —CH2OH or —COOH, and
R4 represents a C1-16 alkyl group having one or more substituents on a terminal carbon atom and/or non-terminal carbon atom(s), a C2-16 alkenyl group having one or more substituents on a terminal carbon atom and/or non-terminal carbon atom(s), or a C2-16 alkynyl group having one or more substituents on a terminal carbon atom and/or non-terminal carbon atom(s).

### Claim 11 (depends on 10)

The kit of claim 10, for use in prevention or treatment of a disease caused by the protozoan.

### Claim 12 (depends on 11)

The kit of claim 11, wherein the protozoan is Trypanosoma.

### Claim 13 (depends on 11)

The kit of claim 11, wherein the protozoan is Cryptosporidium.

### Claim 14 (depends on 10, 11, 12, 13)

The kit of any one of claims 10 to 13, further comprising glycerol.
